Omeros OMER
NASDAQ OMER
$18.95 -0.16 (-0.84%)
At close: Sep 4, 2026 · 4:00 PM EDT

Omeros (OMER) Liabilities and Shareholders Equity (2010 - 2026)

Omeros (OMER) posted Liabilities and Shareholders Equity of $286.2 million for Q1 2026, down 12.12% sequentially from $325.6 million in Q4 2025, and up 21.69% YoY from $235.2 million in Q1 2025.

Analysis

Omeros (OMER) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends

Omeros has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $286.2 million in Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 21.69% year-over-year to $286.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $998.1 million (down 15.55% YoY) and the FY2025 annual result came in at $325.6 million, up 17.52% from the prior year.
  • Liabilities and Shareholders Equity eased to $286.2 million in Q1 2026 per OMER's latest filing, from $325.6 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $591.0 million in Q4 2022 and troughed at $185.7 million in Q3 2025.
  • A 5-year average of $372.9 million and a median of $356.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
  • The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity soared 270.7% in 2022, then sank 46.25% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $591.0 million in 2022, then slumped by 35.99% to $378.3 million in 2023, then fell by 26.75% to $277.1 million in 2024, then grew by 17.52% to $325.6 million in 2025, then slipped by 12.12% to $286.2 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $286.2 million, $325.6 million, and $185.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 10.96 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 4.32 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 9.18 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 5.56 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 19.82 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 2.10 Bn
10 Omeros 1.38 Bn 1.38 Bn 27.73 Mn 286.83 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 286.83 Mn
Mar 31, 2026 286.17 Mn
Dec 31, 2025 325.63 Mn
Sep 30, 2025 185.71 Mn
Jun 30, 2025 200.57 Mn
Mar 31, 2025 235.16 Mn
Dec 31, 2024 277.08 Mn
Sep 30, 2024 313.34 Mn
Jun 30, 2024 356.31 Mn
Mar 31, 2024 437.49 Mn
Dec 31, 2023 378.27 Mn
Sep 30, 2023 493.07 Mn
Jun 30, 2023 527.42 Mn
Mar 31, 2023 560.13 Mn
Dec 31, 2022 590.97 Mn
Sep 30, 2022 457.55 Mn
Jun 30, 2022 345.64 Mn
Mar 31, 2022 369.26 Mn
Dec 31, 2021 419.27 Mn
Sep 30, 2021 123.43 Mn